We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cognizant (CTSH) Set to Buy Azure Specialist 10th Magnitude
Read MoreHide Full Article
Cognizant Technology Solutions (CTSH - Free Report) recently announced that it has entered into an agreement to buy Chicago-based cloud firm 10th Magnitude that focuses on Microsoft’s (MSFT - Free Report) cloud-computing arm Azure.
10th Magnitude offers advisory and managed services, including data-center transformation, application modernization, and data intelligence with AI-driven analytics and insights. Similar to Cognizant, 10th Magnitude is a Microsoft Gold Partner.
Markedly, 10th Magnitude will be integrated into Cognizant’s Microsoft Business Group upon close of the transaction, which is expected in the third quarter of 2020.
Cognizant has been focused on strengthening its footprint in Azure-related services. Notably, the company completed New Signature deal on Aug 18. The transaction expands Cognizant’s hyperscale cloud-advisory services.
Cognizant Technology Solutions Corporation Price, Consensus and EPS Surprise
Undoubtedly, the latest 10th Magnitude deal will further expand Cognizant’s Microsoft Azure expertise.
Acquisitions to Aid Cognizant’s Growth
Acquisitions have played an important part in charting out Cognizant’s growth trajectory by strengthening its digital capabilities, client base and market footprint.
In 2019, Cognizant completed five acquisitions, namely Mustache, Meritsoft, Samlink, Zenith and Contino, which expanded its footprint into SaaS, financial services including banking capabilities, biopharmaceutical and medical-device space, enterprise DevOps, and cloud transformation.
This year, the company has been particularly focusing on augmenting its cloud practices. Apart from New Signature, Cognizant bought privately held global consultancy company Collaborative Solutions, which specializes in Workday (WDAY - Free Report) enterprise cloud applications for financial and human resources.
Additionally, Cognizant acquired Lev, a Salesforce Platinum Partner, specialized in custom cloud solutions. It also bought EI-Technologies, a digital technology consulting firm and leading Salesforce specialist.
Although the acquisitions are expected to have limited revenue contribution, they surely expand Cognizant’s digital endeavors and are expected to boost clientele in the long haul. However, acquisitions like Collaborative and New Signature are likely to keep margins under pressure in the near term.
2020 Revenues Expected to Decline Y/Y
Markedly, for 2020, Cognizant expects revenues to decline between 0.5% and 2% year over year at constant currency to $16.4-16.7 billion range. Management anticipates its top line to suffer from the exit of certain content-services business.
Moreover, Cognizant expects adjusted operating margin to be around 15% in 2020 compared with 16.6% reported in 2019.
The Zacks Consensus Estimate for 2020 revenues is pegged at $16.56 billion, indicating a decline of 1.3% year over year. Moreover, the consensus mark for earnings stands at $3.56 per share, suggesting a decline of 10.8% year over year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Cognizant (CTSH) Set to Buy Azure Specialist 10th Magnitude
Cognizant Technology Solutions (CTSH - Free Report) recently announced that it has entered into an agreement to buy Chicago-based cloud firm 10th Magnitude that focuses on Microsoft’s (MSFT - Free Report) cloud-computing arm Azure.
10th Magnitude offers advisory and managed services, including data-center transformation, application modernization, and data intelligence with AI-driven analytics and insights. Similar to Cognizant, 10th Magnitude is a Microsoft Gold Partner.
Markedly, 10th Magnitude will be integrated into Cognizant’s Microsoft Business Group upon close of the transaction, which is expected in the third quarter of 2020.
Cognizant has been focused on strengthening its footprint in Azure-related services. Notably, the company completed New Signature deal on Aug 18. The transaction expands Cognizant’s hyperscale cloud-advisory services.
Cognizant Technology Solutions Corporation Price, Consensus and EPS Surprise
Cognizant Technology Solutions Corporation price-consensus-eps-surprise-chart | Cognizant Technology Solutions Corporation Quote
Undoubtedly, the latest 10th Magnitude deal will further expand Cognizant’s Microsoft Azure expertise.
Acquisitions to Aid Cognizant’s Growth
Acquisitions have played an important part in charting out Cognizant’s growth trajectory by strengthening its digital capabilities, client base and market footprint.
In 2019, Cognizant completed five acquisitions, namely Mustache, Meritsoft, Samlink, Zenith and Contino, which expanded its footprint into SaaS, financial services including banking capabilities, biopharmaceutical and medical-device space, enterprise DevOps, and cloud transformation.
This year, the company has been particularly focusing on augmenting its cloud practices. Apart from New Signature, Cognizant bought privately held global consultancy company Collaborative Solutions, which specializes in Workday (WDAY - Free Report) enterprise cloud applications for financial and human resources.
Further, this Zacks Rank #3 (Hold) company bought Code Zero, a provider of consulting and implementation services that strengthens its cloud-solutions portfolio and Salesforce (CRM - Free Report) domain expertise. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Additionally, Cognizant acquired Lev, a Salesforce Platinum Partner, specialized in custom cloud solutions. It also bought EI-Technologies, a digital technology consulting firm and leading Salesforce specialist.
Although the acquisitions are expected to have limited revenue contribution, they surely expand Cognizant’s digital endeavors and are expected to boost clientele in the long haul. However, acquisitions like Collaborative and New Signature are likely to keep margins under pressure in the near term.
2020 Revenues Expected to Decline Y/Y
Markedly, for 2020, Cognizant expects revenues to decline between 0.5% and 2% year over year at constant currency to $16.4-16.7 billion range. Management anticipates its top line to suffer from the exit of certain content-services business.
Moreover, Cognizant expects adjusted operating margin to be around 15% in 2020 compared with 16.6% reported in 2019.
The Zacks Consensus Estimate for 2020 revenues is pegged at $16.56 billion, indicating a decline of 1.3% year over year. Moreover, the consensus mark for earnings stands at $3.56 per share, suggesting a decline of 10.8% year over year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>